AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Launches Investigation into Aquestive Therapeutics

Faruqi & Faruqi, LLP, a prominent national securities law firm, has initiated an investigation into Aquestive Therapeutics, Inc. (NASDAQ: AQST) following a significant drop in its stock price. This investigation comes after the company reported that the U.S. Food and Drug Administration (FDA) identified deficiencies in its New Drug Application (NDA) for Anaphylm, an innovative sublingual film designed for treating severe allergic reactions, including anaphylaxis. On Friday, shares of Aquestive Therapeutics fell nearly 40% intraday as investors reacted to the news, which raised serious concerns about the application's potential approvability ahead of the FDA's target action date set for January 31, 2026.

Faruqi & Faruqi emphasizes the importance of addressing investor concerns and is urging those who have experienced significant losses in their investments in Aquestive stock or options to reach out for a consultation. The firm’s securities litigation partner, James (Josh) Wilson, is encouraging affected investors to discuss their legal rights and potential claims related to the situation.

Since its inception in 1995, Faruqi & Faruqi has successfully recovered hundreds of millions of dollars for investors, making it a well-respected player in the field of securities law. Investors seeking more information about the investigation can visit the firm's website or contact Josh Wilson directly via provided phone numbers. The investigation aims to ensure that justice is served for shareholders who may have been adversely affected by the company’s recent disclosures.

For those interested in receiving updates or additional developments regarding the investigation, Faruqi & Faruqi maintains an active presence on LinkedIn, X (formerly Twitter), and Facebook.

The recent announcement from Faruqi & Faruqi, LLP regarding an investigation into Aquestive Therapeutics (NASDAQ: AQST) has raised alarm bells for current and prospective investors following a significant drop in the company's stock price. Shares plummeted nearly 40% after the FDA identified deficiencies in the company’s New Drug Application (NDA) for Anaphylm, which is designed to address severe allergic reactions. This situation warrants careful analysis for those involved in the AQST market.

Investors are advised to remain vigilant. While the FDA’s communication regarding the deficiencies raises serious concerns about Anaphylm's approvability, it could represent a critical juncture for the company. Should the issues identified be resolvable, there may be a pathway for recovery; however, the current uncertainty makes this a high-risk investment.

For those who have suffered significant losses, it may be prudent to consider engaging with legal counsel to explore potential claims. Involvement in litigation, as indicated by Faruqi & Faruqi, could provide a means of mitigating losses, although it also involves additional time and potential costs.

From a market perspective, a further examination of the FDA's feedback may provide insight into whether this drop in stock price is justified or an overreaction. Investors should assess their risk tolerance and possibly consider diversifying their portfolios to hedge against potential further declines in AQST.

In conclusion, investors should weigh the potential risks against any remaining upside and keep a close watch on further developments. Engaging with financial advisors for personalized guidance during this tumultuous time may prove beneficial as the situation continues to evolve.